As clinical trials play a crucial role in advancing medical knowledge, how can we ensure that their benefits do not level devil lead to the over-medicalization of normal life processes?
Specifically, how do we navigate this balance in the context of pharmaceutical companies potentially influencing trials to expand markets for their products?